A5033190268- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Bioinformatics and Genomic Networks
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Genetic Associations and Epidemiology
- Statistical Distribution Estimation and Applications
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- COVID-19 diagnosis using AI
- Protein Degradation and Inhibitors
- Cancer therapeutics and mechanisms
- COVID-19 Clinical Research Studies
- Advanced Causal Inference Techniques
- Statistical Methods in Clinical Trials
- Cancer-related Molecular Pathways
- Angiogenesis and VEGF in Cancer
- vaccines and immunoinformatics approaches
- Acute Myeloid Leukemia Research
- Bacterial Infections and Vaccines
- Chromatin Remodeling and Cancer
- PARP inhibition in cancer therapy
- Monoclonal and Polyclonal Antibodies Research
University of Minnesota
2021-2025
University of International Business and Economics
2024
University of Minnesota System
2021-2024
Minneapolis Institute of Arts
2024
ImmunoGen (United States)
2019-2023
Dana-Farber Cancer Institute
2023
Vall d'Hebron Institute of Oncology
2023
Vall d'Hebron Hospital Universitari
2023
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2023
St John of God Subiaco Hospital
2023
Purpose Epidermal growth factor receptor (EGFR) –tyrosine kinase inhibitors have proven efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be efficacious the adjuvant setting. Patients and Methods An international randomized, double-blind, placebo-controlled study was conducted patients with completely resected IB to IIIA NSCLC whose tumors expressed EGFR protein by immunohistochemistry or amplification fluorescence situ hybridization. were assigned...
PURPOSE Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA a single-arm, phase II study evaluating efficacy safety of MIRV PROC. METHODS enrolled FRα-high PROC who had received one to three prior therapies, including required bevacizumab. The primary end point was confirmed objective response...
Evaluate the antitumor activity and safety profile of combination mirvetuximab soravtansine bevacizumab in patients with platinum-resistant ovarian cancer.Patients recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was ≤6 months, were administered (6 mg/kg adjusted ideal body weight) (15 mg/kg), intravenously, once every 3 weeks. Eligibility included FRα expression by immunohistochemistry (IHC; ≥25% cells ≥2+ intensity). Prior...
To handle composite endpoints, the win ratio has been applied to data analysis and design of clinical trials. Its interpretation, however, is not always clear, it could ties differently. We address these two aspects. First, we express as a proportions, namely, proportion patient-level comparisons in which experimental treatment “wins” over control divided by for control, taking into account priority order components. This equivalent form, can ease communication trial stakeholders—especially...
The win ratio method has received much attention in methodological research, ad hoc analyses, and designs of prospective studies. As the primary analysis, it supported approval tafamidis for treatment cardiomyopathy to reduce cardiovascular mortality cardiovascular-related hospitalization. However, its dependence on censoring is a potential shortcoming. In this article, we propose inverse-probability-of-censoring weighting (IPCW) adjusted statistic (i.e., IPCW-adjusted statistic) overcome...
7501 Background: The proven efficacy of E in advanced NSCLC warranted its evaluation the adjuvant setting. BR.21 data suggested pts with EGFR positive tumors (IHC/FISH) were more likely to benefit from E. Methods: Completely resected IB-IIIA randomized 2:1 receive 150 mg qd or P for 2 years. Pts stratified according stage, histology, prior chemotherapy, smoking status, FISH and country. primary endpoint was disease free survival (DFS) full analysis set (FAS). Secondary endpoints included...
5512 Background: SORAYA is a global single arm phase 3 study evaluating MIRV in patients (pts) with FRα high platinum-resistant ovarian cancer (PROC). an antibody drug conjugate comprising FRα-binding antibody, cleavable linker, and maytansinoid DM4, potent tubulin-targeting agent. In this study, demonstrated activity broad population of PROC, regardless number prior lines therapy or PARPi (Matulonis, SGO 2022). Here we describe details response to treatment important for clinical decision...
Abstract For composite outcomes whose components can be prioritized on clinical importance, the win ratio, net benefit and odds apply that order in comparing patients pairwise to produce wins subsequently proportions. Because these three statistics are derived using same proportions they test hypothesis of equal probabilities two treatment groups, we refer them as . These methods, particularly ratio benefit, have received increasing attention methodological research design analysis trials....
Abstract Motivation Many diseases are complex heterogeneous conditions that affect multiple organs in the body and depend on interplay between several factors include molecular environmental factors, requiring a holistic approach to better understand disease pathobiology. Most existing methods for integrating data from sources classifying individuals into one of classes or groups have mainly focused linear relationships despite complexity these relationships. On other hand, nonlinear...
Systems vaccinology studies have been used to build computational models that predict individual vaccine responses and identify the factors contributing differences in outcome. Comparing such is challenging due variability study designs. To address this, we established a community resource compare predicting B. pertussis booster generate experimental data for explicit purpose of model evaluation. We here describe our second prediction challenge using this resource, where benchmarked 49...
5504 Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, potent tubulin-targeting agent. As part of Phase 1b FORWARD II trial (NCT02606305), combination MIRV with bevacizumab (BEV) was evaluated in pts FRα-positive (medium/high expression; ≥50%/ ≥75% cells PS2+ staining intensity), platinum agnostic ovarian cancer, defined as either resistant (PROC) (recurrence within 6 months after last dose) or sensitive...
7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to TKIs. Methods: RADIANT was a randomized trial of postoperative E v P completely resected stage IB-IIIA were stratified by histology (adenocarcinoma, other), (IB, II, IIIA), adjuvant chemotherapy (yes, no), smoking history (never, current/former), FISH (positive, negative/undetermined) and country. 2:1 receive 150mg/day for up 2...
(Abstracted from J Clin Oncol 2023;41(13):2436–2445 Approximately 80% of patients with ovarian cancer experience recurrence after platinum-based chemotherapy, and unfortunately nearly all will eventually develop platinum-resistant (PROC). Treatment in this setting consists nonplatinum chemotherapy or without bevacizumab; however, each successive line therapy PROC is associated progressively lower response rates.
TPS7563 Background: Overexpression of CD123 occurs in multiple hematological malignancies, including acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), lymphoblastic (ALL) and others, thus making this antigen an attractive target for the development new therapeutics. IMGN632 is a CD123-targeting antibody-drug conjugate (ADC) comprising novel anti-CD123 antibody coupled, via peptide linker, to unique DNA-alkylating cytotoxic payload recently developed IGN...
ABSTRACT Statistical approaches that successfully combine multiple datasets are more powerful, efficient, and scientifically informative than separate analyses. To address variation architectures correctly comprehensively for high-dimensional data across sample sets (ie, cohorts), we propose augmented reduced rank regression (maRRR), a flexible matrix factorization method to concurrently learn both covariate-driven auxiliary structured variations. We consider nuclear norm objective is...
TPS6103 Background: Elevated FRα expression is a characteristic of several solid tumors, including epithelial ovarian cancer (EOC), thereby providing an attractive candidate for targeted therapeutic approaches. Mirvetuximab soravtansine antibody-drug conjugate (ADC) comprising FRα-binding antibody, cleavable linker, and the maytansinoid DM4, potent tubulin-targeting agent that has shown consistent meaningful single clinical activity, along with favorable tolerability, in patients high...
<h3>Objectives</h3> Mirvetuximab soravtansine (MIRV) is a first-in-class ADC comprising folate receptor-α (FRα)-binding antibody, cleavable linker, and maytansinoid DM4 payload. As part of the phase 1b/2 trial (NCT02606305), efficacy safety MIRV carboplatin (carbo) were evaluated in patients with recurrent FRα-positive platinum sensitive ovarian cancer (PSOC) measured by immunohistochemistry (PS2+ ≥25%; table 1). <h3>Methods</h3> Eighteen received carbo intravenously on Day 1 3-week cycle...
Abstract Background Schizophrenia is a common psychiatric disease with high hereditary. The identification of schizophrenia risk genes (SRG) has shed light on its pathophysiological mechanisms. Mouse genetic models have been widely used to study the function SRG in brain cell type specific fashion. However, whether cellular expression pattern conserved between human and mouse not thoroughly studied. Results We analyzed single-cell transcription 180 from primary visual cortex (V1). compared...
6004 Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, potent tubulin-targeting agent. As part of Phase 1b FORWARD II trial (NCT02606305), combination MIRV with bevacizumab (BEV) was evaluated in pts FRα-positive (medium/high expression; ≥ 50%/ ≥75% cells PS2+ staining intensity), platinum agnostic ovarian cancer, defined as either resistant (PR) (recurrence within 6 months after last dose) or sensitive (PS)...